 |
0 Diseases |  |
61 Trials |
|
61 Trials |  |
3860 News |  |
| «12...345678910111213...5758» |
- | Jakafi (ruxolitinib) / Novartis, Incyte
Journal: CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy. (Pubmed Central) - Jan 3, 2024
Bioinformatics analysis identified genes whose expression was correlated with CD45 expression such as JAK2, ACTR2, THAP3 Serglycin, and PBX-1 genes, as well as licensed drugs (alendronate, allopurinol, and balsalazide), which could be repurposed as CD45 inhibitors which effectively increases sensitivity to cytarabine and ruxolitinib at low doses. Therefore, CD45 inhibition could be explored as a potential therapeutic partner for treatment of myeloid malignancies in combination with chemotherapy such as cytarabine especially for elderly patients and those showing chemotherapy resistance.
- ||| allopurinol / Generic mfg.
Journal, Adverse events: Comparison of Class-Specific Side Effects Across Preventative Pharmacologic Therapies for Kidney Stone Disease. (Pubmed Central) - Dec 24, 2023
In adjusted analyses, compared to alkali citrate, thiazides were associated with a higher odds of hypokalemia (OR=2.01, 95% CI 1.44-2.81) and hyperglycemia/diabetes (OR=1.52, 95% CI 1.26-1.83), while allopurinol was associated with a higher odds of hyperglycemia/diabetes (OR=1.34, 95% CI 1.02-1.75). These data provide evidence to support clinical guidelines that recommend periodic serum testing to assess for adverse effects from preventive pharmacologic therapy.
- || febuxostat / Generic mfg.
Review, Journal: Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials. (Pubmed Central) - Dec 20, 2023
Cardiovascular outcomes in the majority of White males with gout treated with febuxostat were reassuring when compared with allopurinol. Further studies are needed to draw conclusions in patients with severe cardiovascular disease.
- | febuxostat / Generic mfg., allopurinol / Generic mfg.
Retrospective data, Journal: Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. (Pubmed Central) - Dec 19, 2023
Further studies are needed to draw conclusions in patients with severe cardiovascular disease. Febuxostat (80
- || Review, Journal: Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies. (Pubmed Central) - Dec 17, 2023
Uric acid-lowering efficacy is not an independent factor for the renal safety risk of different URAT1 inhibitors, and structural differences could be responsible for the difference. The adverse renal effects of URAT1 inhibitors are dose-dependent, and the combination with high doses of XOIs can significantly reduce the renal safety risk by reducing uric acid excretion by the kidneys.
- | allopurinol / Generic mfg.
Journal: Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial. (Pubmed Central) - Dec 17, 2023
P3
Therefore, allopurinol may constitute a promising agent for patients with hepatic decompensation. These positive outcomes could be a result of its ability to reduce bacterial translocation and inflammation.
- | allopurinol / Generic mfg.
Journal, Immunomodulating: Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). (Pubmed Central) - Dec 14, 2023
These positive outcomes could be a result of its ability to reduce bacterial translocation and inflammation. Thiopurine-allopurinol therapy is safe and mitigates thiopurine adverse effects, thus enhancing tolerability without compromising efficacy (ACTRN12613001347752).
- Elitek (rasburicase) / Sanofi
A Deadly Triad: Metastatic Esophageal Adenocarcinoma with Alpha-Fetoprotein Production, Liver Capsular Tear after Needle Biopsy, and Spontaneous Solid Tumor Lysis Syndrome (Babcock #6 (Sunset Center)) - Dec 13, 2023 - Abstract #WRMC2024WRMC_398;
Metastatic Esophageal Adenocarcinoma holds a relative 5-year survival rate of only 6%. AFP-producing Esophageal tumors are rare and warrant further oncologic investigation and research to provide appropriate and timely care to patients with early and rapidly progressing presentation.
- Decadron (dexamethasone) / Merck (MSD), Elitek (rasburicase) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
HIV-Associated Burkitt Lymphoma presented as Submandibular Infection (Ninth Avenue & Dolores St.) - Dec 13, 2023 - Abstract #WRMC2024WRMC_246;
He was admitted and treated with IV Ampicillin/Sulbactam and discharged a day later with a 10-day course of Amoxicillin/Clavulanic Acid...A month later the patient was admitted for treatment with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-R-EPOCH)...He received Decadron and swelling improved...Allopurinol 300mg was given daily, but no rasburicase was indicated because uric acid was not elevated. Sagital view of submandibular Burkitts Lymphoma.
- Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
Incidence of Laboratory Tumor Lysis Syndrome in CAR T-Cell Recipients () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1305;
Out of the two patients with protocol defined TLS, only one had possible TLS with stage 3 AKI, a SCr peak at 1.7 mg/dL from a baseline of 0.5 mg/dL, with extensive disease (mediastinal mass >10 cm) and a complicated course. A risk-stratified approach may be warranted to identify high risk patients with certain characteristics (i.e., bulky tumor with progressive disease) who would benefit from prophylactic allopurinol for TLS prevention.
- | allopurinol / Generic mfg.
Journal: Unraveling the Complexities of DRESS: Insights into clinical, laboratory, and histopathologic features of a case series from an Italian tertiary center. (Pubmed Central) - Dec 11, 2023
The study observed a slight predominance of women, with antimicrobials and allopurinol identified as the main causative drugs...The prognosis of DRESS depended on early identification, discontinuation of the causative agent, and appropriate therapy. Systemic corticosteroids were the primary treatment option.
- || allopurinol / Generic mfg.
Retrospective data, Review, Journal: Efficacy of Allopurinol in Improving Endothelial Dysfunction: A Systematic Review and Meta-Analysis. (Pubmed Central) - Dec 10, 2023
Systemic corticosteroids were the primary treatment option. While allopurinol may improve endothelial function in various patient populations, further high-quality randomized controlled trials are needed to determine its efficacy in preventing cardiovascular disease exacerbation.
- | allopurinol / Generic mfg.
Retrospective data, Journal: Flares in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: a retrospective study. (Pubmed Central) - Dec 5, 2023
While allopurinol may improve endothelial function in various patient populations, further high-quality randomized controlled trials are needed to determine its efficacy in preventing cardiovascular disease exacerbation. No abstract available
- | Journal: Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. (Pubmed Central) - Dec 5, 2023
Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.
- | allopurinol / Generic mfg.
New P1/2 trial: An evidence-based evaluation study of integrated Chinese and Western medicine treatment for the preclinical phase of gout (EUDRACT) - Dec 5, 2023
P1/2, N=513, Not yet recruiting, Sponsor: The First Affiliated Hospital of Hu'nan University of Chinese Medicine; Hu'nan University of Chinese Medicine
Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes. .
- || febuxostat / Generic mfg.
Review, Journal: Celebrating Versatility: Febuxostat's Multifaceted Therapeutic Application. (Pubmed Central) - Nov 25, 2023
Emerging research explores febuxostat's roles in cardiovascular health, neurological disorders, rheumatoid arthritis, and cancer therapy, driven by its anti-inflammatory and antioxidative properties. Future directions include personalized medicine, combination therapies, mechanistic insights, and ongoing long-term safety monitoring, collectively illuminating the promising landscape of febuxostat's multifaceted therapeutic potential.
- | febuxostat / Generic mfg., allopurinol / Generic mfg.
Journal: Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. (Pubmed Central) - Nov 25, 2023
The study found that the CAP score decreased significantly in the allopurinol group (p = 0.009), but the decline in the febuxostat or lifestyle groups was non-significant (p = 0.189 and 0.054, respectively). The SUA levels were significantly reduced in both the allopurinol and febuxostat groups (p < 0.001), with no statistical difference between the two groups (p = 0.496).
- || allopurinol / Generic mfg.
Journal, Adverse drug reaction: Cutaneous adverse drug reactions. (Pubmed Central) - Nov 19, 2023
All drugs can cause cutaneous ADRs, the most commonly implicated being antibiotics (especially aminopenicillins and sulfonamides), anticonvulsants, allopurinol, antineoplastic drugs, non-steroidal anti-inflammatory drugs and iodinated contrast media...To determine the origin of a rash, a logical approach based on clinical characteristics, chronologic factors and elimination of differential diagnosis (especially infectious etiologies) is required, completed with a literature search. Reporting to pharmacovigilance system is therefore essential both to analyze drug causality at individual level, and to contribute to knowledge of the drug at population level, especially for serious cutaneous ADRs or in cases involving newly marketed drugs.
- | allopurinol / Generic mfg.
Journal, HEOR: Health-related quality of life by gout severity in women and men with gout in primary care: results from a questionnaire study in Western Sweden. (Pubmed Central) - Nov 17, 2023
Allopurinol use was more frequent in those with mild disease...When excluding those with a flare in the past month, the HRQoL was still worse in severe gout (vs mild), although differences were attenuated and not statistically significant for the PCS and for women. Gout severity, defined as the number of flares during the past year, was associated with significant reductions in HRQoL.
- Krystexxa (pegloticase) / Amgen, Kineret (anakinra) / SOBI
Acute Pain Secondary to Debilitating Polyarticular Gout on the Inpatient Rehabilitation Unit: A Case Report () - Nov 16, 2023 - Abstract #AAPMR2023AAPMR_490;
Consulting rheumatologists recommended treatment with anakinra, steroids, colchicine, and allopurinol, but deferred initiation of uricase enzymes. As physiatrists, patient advocacy is crucial in the management of complex patient diagnoses and systems such as interdisciplinary teams, hospitals, and insurance companies.
- | allopurinol / Generic mfg.
Journal: Can Smartphone Notifications Help with Gout Management? A Feasibility Study. (Pubmed Central) - Nov 15, 2023
Adherence-targeted notifications have the potential to be an effective and scalable approach to supporting medication adherence in gout patients. Further research is needed with larger samples to refine the components of the intervention and explore its optimal implementation.
- | colchicine / Generic mfg.
Journal: Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink. (Pubmed Central) - Nov 13, 2023
Adverse events were more common when allopurinol was initiated with prophylaxis, particularly diarrhoea with colchicine. Other events were uncommon, providing reassurance for patients and clinicians to enable shared decision-making.
- | allopurinol / Generic mfg.
Preclinical, Journal: THE THERAPEUTIC EFFECT OF ALLOPURINOL IN FATTY LIVER DISEASE IN RATS. (Pubmed Central) - Nov 4, 2023
Other events were uncommon, providing reassurance for patients and clinicians to enable shared decision-making. The allopurinol group had lower histopathological scores, IL-1 and IL-2 immunoexpression levels in the liver compared to the saline group (2.13
- | Krystexxa (pegloticase) / Amgen, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
Journal: Drugs for gout. (Pubmed Central) - Nov 3, 2023
The allopurinol group had lower histopathological scores, IL-1 and IL-2 immunoexpression levels in the liver compared to the saline group (2.13 No abstract available
- | Journal: Contributing Factors of Diabetes Mellitus among Patients with Gout (Results of the Long-Term Prospective Study). (Pubmed Central) - Nov 3, 2023
No abstract available To identify the factors associated with the risk of developing T2DM, multivariate logistic regression was used, which included sex; T2DM in relatives; insufficient physical activity; unbalanced diet; age
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6565;
56 pts received allopurinol =72 hours prior to starting ven, 21 received =2L of IV fluid per day starting at least the day prior to ven, and 56 had TLS labs measured every 8-12 hours during the first 3 days following ven initiation...We defined significant TLS as pts who required hospitalization (if started treatment outpatient) or ICU transfer, received rasburicase, developed AKI, or had treatment held due to TLS...Of the pts who developed significant TLS, a majority had spontaneous TLS; only 5 pts had significant TLS occur after starting ven. We also found that the Howard criteria for TLS better identify pts who will have adverse outcomes from TLS and may be a more clinically meaningful set of criteria to use in future studies.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysi... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6107;
P2
On days of dose escalation, ppx additionally included kayexalate, rasburicase, and IV normal saline on D1 and D2 of each dose escalation...Eliminating the need for hospitalization during V dose escalation may enhance patient and provider convenience and decrease the economic burden of this regimen. This study is ongoing; efficacy results of this MRD-guided approach to V/O are forthcoming.
- Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_4678;
Methods We conducted a retrospective analysis of pts =18 years of age with newly diagnosed or relapsed/refractory AML treated with a standard dose hypomethylating agent (HMA), either azacitidine or decitabine, and VEN without a dose ramp-up (initiated at 400mg daily or 100mg daily if on concomitant voriconazole or posaconazole) at Thomas Jefferson University Hospital from January 1, 2018- August 1, 2021...Sixty-one pts (68%) were receiving allopurinol prophylaxis at the time of HMA-VEN administration...Fifteen pts (17%) were on medications, such as thiazide diuretics, aspirin, or levodopa, that can increase the risk of TLS at the time of treatment...Starting pts with AML on full dose VEN on day 1, regardless of white blood cell count, renal function, or concomitant medications, appears safe and could be implemented in clinical practice and clinical trials moving forward. This would simplify dosing for pts, pharmacists, and providers and allow for easier initiation of therapy.
- | allopurinol / Generic mfg.
Trial completion, Trial primary completion date, HEOR: Allopurinol and Quality of Life in Liver Cirrhosis (clinicaltrials.gov) - Oct 30, 2023
P2/3, N=100, Completed, Sponsor: Tanta University
This would simplify dosing for pts, pharmacists, and providers and allow for easier initiation of therapy. Recruiting --> Completed | Trial primary completion date: May 2023 --> Jan 2023
- | thapsigargin / University of Nottingham, Pirbright Institute
Journal: Endoplasmic Reticulum Stress Promotes the Expression of TNF-? in THP-1 Cells by Mechanisms Involving ROS/CHOP/HIF-1? and MAPK/NF-?B Pathways. (Pubmed Central) - Oct 28, 2023
and MAPK/NF-?B dependent mechanisms. This study also highlights the therapeutic potential of antioxidants in inflammatory conditions involving metabolic/ER stresses.
- | allopurinol / Generic mfg.
Journal: Clinical and Laboratory Response of Domiciled Dogs with Visceral Leishmaniasis Treated with Miltefosine and Allopurinol. (Pubmed Central) - Oct 27, 2023
The continuous use of allopurinol contributes to control of the disease in dogs. These findings provide valuable insights into the response of dogs treated in natural conditions, offering essential information for veterinarians and public health authorities.
- | febuxostat / Generic mfg., allopurinol / Generic mfg.
Journal: Comparative studies of xanthine oxidase inhibitors viz allopurinol and febuxostat against induced hyperuricemia in poultry model. (Pubmed Central) - Oct 26, 2023
Further haematological, biochemical, patho-morphological and ultrastructural studies using transmission electron microscopy were carried out to evaluate the pathology and thus, ameliorative effect of allopurinol and febuxostat. The findings proved that allopurinol and febuxostat carries definite ameliorative potential as an anti-hyperuricemic and anti-gout potential in poultry, which was better expressed by febuxostat as compared to allopurinol.
- | allopurinol / Generic mfg.
Preclinical, Journal: Role of CD44 expressed in renal tubules during maladaptive repair in renal fibrogenesis in an allopurinol-induced rat model of chronic kidney disease. (Pubmed Central) - Oct 25, 2023
Overall, these data indicated that dilated/atrophic TECs underwent a partial epithelial-mesenchymal transition (pEMT) and that CD44 promoted renal fibrogenesis via induction of ECM production in failed-repair TECs exhibiting pEMT. CD44 was detected in the urine and serum of APL-treated rats, which may reflect the expression of CD44 in the kidney.
- AR882 / Arthrosi
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography (Room 6A-B; in person) - Oct 24, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4581;
In this global study, six-month treatment of AR882 demonstrated safe and efficacious sUA lowering, tophus resolution and total crystal volume dissolution in gout patients with various demographics and baseline characteristics. AR882 may offer improved efficacy and better safety compared to existing therapies in the treatment of patients with gout, including those with both clinically visible and subclinical crystal deposition.
- | Krystexxa (pegloticase) / Amgen, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
Journal: Comparison table: Some drugs for gout. (Pubmed Central) - Oct 24, 2023
AR882 may offer improved efficacy and better safety compared to existing therapies in the treatment of patients with gout, including those with both clinically visible and subclinical crystal deposition. No abstract available
- | allopurinol / Generic mfg.
Journal: Granulomatous tattoo reaction treated with topical allopurinol. (Pubmed Central) - Oct 23, 2023
Oral allopurinol has been proven to be effective for the management of granulomatous reactions to tattoos. Based on the significant improvement we have described in our patient, we recommend new studies to reveal all the potential benefits of the topical use of allopurinol for the treatment of granulomatous reactions to tattoo ink.
- | Stivarga (regorafenib) / Bayer, allopurinol / Generic mfg.
Journal, Metastases: Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer. (Pubmed Central) - Oct 22, 2023
These associations were no longer significant after Bonferroni correction for multiple testing. Therefore, regorafenib-induced EM in Japanese patients appears to be associated with specific HLA haplotypes but further validation is needed.
- | febuxostat / Generic mfg., allopurinol / Generic mfg.
Journal: Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. (Pubmed Central) - Oct 16, 2023
Several patient-level factors were predictive of SU goal achievement among gout patients administered treat-to-target ULT. Approaches that accurately predict individual responses to treat-to-target ULT hold promise in facilitating personalized management and improving outcomes in patients with gout.
- | allopurinol / Generic mfg.
Journal: High Performance Liquid Chromatography Analysis and Description of Purine Content of Diets Suitable for Dogs with Leishmania Infection during Allopurinol Treatment-A Pilot Trial. (Pubmed Central) - Oct 14, 2023
Differences in the purine content of commercially available diets need to be considered. Awareness has to be raised when selecting diets for dogs with Leishmania infections during allopurinol treatment in order to minimise the risk of urolith formation.
- |||| ABP-671 / Jiangsu Atom Bioscience and Pharma
Enrollment open: Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout (clinicaltrials.gov) - Oct 12, 2023
P2b, N=580, Recruiting, Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
Awareness has to be raised when selecting diets for dogs with Leishmania infections during allopurinol treatment in order to minimise the risk of urolith formation. Not yet recruiting --> Recruiting
- | allopurinol / Generic mfg.
Enrollment open: ALL-VASCOR: The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With Cardiovascular Risk (clinicaltrials.gov) - Oct 12, 2023
P3, N=1116, Recruiting, Sponsor: Poznan University of Medical Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || allopurinol / Generic mfg.
Review, Journal: Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. (Pubmed Central) - Oct 11, 2023
Multiple dose titrations commonly needed to optimize first-line allopurinol ULT monotherapy, and substantial potential toxicities and other limitations of approved, marketed oral monotherapy ULT drugs, promote hyperuricemia undertreatment...Evolving ULT approaches include administering selected gut anaerobic purine degrading bacteria (PDB), modulating intestinal urate transport, and employing liver-targeted xanthine oxidoreductase mRNA knockdown. Last, emerging measures to decrease the immunogenicity of systemically administered recombinant uricases should simplify treatment regimens and further improve outcomes in managing the most severe gout phenotypes.
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Review, Journal: A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis. (Pubmed Central) - Oct 10, 2023
Probiotics are effective in preventing pouchitis after IPAA. Antibiotics, including ciprofloxacin and metronidazole, are likely effective in treating active pouchitis.
- | allopurinol / Generic mfg.
Journal: Design of 3-phenylcoumarins and 3-thienylcoumarins as potent xanthine oxidase inhibitors: synthesis, biological evaluation and docking studies. (Pubmed Central) - Oct 6, 2023
3-(3'-Bromophenyl)-5,7-dihydroxycoumarin (compound 11) proved to be the most potent XO inhibitor, with an IC50 of 91 nM, being 162 times better than allopurinol, one of the reference controls...In addition, they proved to be non-cytotoxic in a Caco-2 cells viability assay. Molecular docking studies have been carried out to correlate the compounds' theoretical and experimental binding affinity to the XO binding pocket.
- | allopurinol / Generic mfg.
Preclinical, Journal: Honey Mushroom, Armillaria mellea (Agaricomycetes) and Its Fermentation Products Target Regulation of OAT1/OAT3 Proteins to Reduce Hyperuricemia in Mice. (Pubmed Central) - Oct 5, 2023
Molecular docking studies have been carried out to correlate the compounds' theoretical and experimental binding affinity to the XO binding pocket. Armillaria mellea and its fermentation products can treat hyperuricemia by up-regulating OAT1 protein and OAT3 protein, reducing uric acid content in mice.
- | allopurinol / Generic mfg.
Observational data, Journal: Knowledge and attitudes of gout patients and their perspectives about diagnosis and management: A cross-sectional study in Saudi Arabia. (Pubmed Central) - Oct 3, 2023
The participants expressed a significant degree of satisfaction with the impact of gout management on their occupational performance, work-life balance, and professional plans. Additional research is necessary to ascertain the risk factors associated with gout and provide suitable preventative interventions.
- | febuxostat / Generic mfg., allopurinol / Generic mfg.
Journal: Gout and the Prevalence of Dementia: A Nationwide Population-Based Study. (Pubmed Central) - Oct 2, 2023
This study demonstrated a relatively low prevalence of dementia in patients with gout. Gout, characterized by hyperuricemia, might be associated with a reduced risk of dementia.
- ||| febuxostat / Generic mfg., allopurinol / Generic mfg.
Journal, Adverse events: Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System. (Pubmed Central) - Sep 28, 2023
Gout, characterized by hyperuricemia, might be associated with a reduced risk of dementia. Compared with allopurinol, febuxostat may increase cardiovascular toxicity in patients with gout.
- | indomethacin / Generic mfg., allopurinol / Generic mfg.
Journal: Anti-Hyperuricemic, Anti-Arthritic, Hemolytic Activity and Therapeutic Safety of Glycoconjugated Triazole-Phthalimides. (Pubmed Central) - Sep 28, 2023
Similarly, the phthalimides showed a low degree of erythrocyte hemolysis (<3%). Our data demonstrate that the new glycoconjugate triazole-phthalimides have potential to treat hyperuricemia and its secondary complications, such as gouty arthritis, with a low to non-significant rate of erythrocytes hemolysis, genotoxicity and mutagenicity making these molecules strong candidates as pharmaceutical agents for treatment requiring uric-acid-lowering therapy.
- | Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai
New P1 trial: Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia (clinicaltrials.gov) - Sep 28, 2023
P1b, N=20, Recruiting, Sponsor: Urica Therapeutics Inc.